Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia.
Int J Mol Sci. 2021 Feb 6;22(4):1656. doi: 10.3390/ijms22041656.
The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.
1996 年雌激素受体β（ERβ）的发现为不同类型癌症的诊断和治疗开辟了新的视角。在这里，我们回顾了目前关于其在内分泌相关癌症（乳腺癌、前列腺癌和甲状腺癌以及结直肠癌）中的作用的研究知识。我们还讨论了其在肿瘤发生中的作用存在争议的原因，以及为什么它尚未作为临床实践中的生物标志物使用。鉴于诊断和治疗将受益于引入新的生物标志物，我们提出了克服阐明 ERβ作用中的矛盾的方法。
